Optimizing Patient-Centric Clinical Outcome Assessments for Use in Parkinson's Disease Clinical Trials: Critical Path for Parkinson's Multistakeholder Initiative

被引：0

作者：

Speck, R. ^{[1
]}

Trundell, D. ^{[2
]}

Cedarbaum, J. M. ^{[3
]}

Campbell, M. ^{[4
]}

Chin, P. S. ^{[5
]}

Crawford, S. ^{[6
]}

Dam, T. ^{[7
]}

Dexter, D. T. ^{[8
]}

Goldfine, A. M. ^{[9
]}

Klapper, K. ^{[1
]}

Kopil, C. M. ^{[10
]}

Lee, S. J. ^{[11
]}

Marek, K. ^{[12
]}

Matthews, H. ^{[13
]}

Mestre, T. ^{[14
]}

Morel, T. ^{[15
]}

Minchik, M. ^{[1
]}

Muller, M. L. T. M. ^{[1
]}

Schroeder, K. ^{[16
]}

Simuni, T. ^{[17
]}

Stebbins, G. T. ^{[18
]}

Yan, C. H. ^{[19
]}

Zeissler, M. L. ^{[20
]}

Stephenson, D. ^{[1
]}

机构：

[1] Crit Path Inst, Tucson, AZ USA

[2] Roche Prod Ltd, Welwyn Garden City, Herts, England

[3] Coeruleus Clin Sci LLC, Woodbridge, CT USA

[4] US FDA, Off Neurosci, Silver Spring, MD USA

[5] Denali Therapeut, San Francisco, CA USA

[6] Takeda, Cambridge, MA USA

[7] Biogen, Cambridge, MA USA

[8] Parkinsons UK, London, England

[9] GlaxoSmithKline, Collegeville, PA USA

[10] Michael J Fox Fdn, New York, NY USA

[11] Merck & Co Inc, Kenilworth, NJ USA

[12] Inst Neurodegenerat Disorders, New Haven, CT USA

[13] Cure Parkinsons, London, England

[14] Univ Ottawa, Ottawa, ON, Canada

[15] UCB Pharmaceut, Brussels, Belgium

[16] Parkinsons Fdn, Miami, FL USA

[17] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[18] Rush Univ, Chicago, IL 60612 USA

[19] AbbVie Inc, Chicago, IL USA

[20] Univ Plymouth, Plymouth, Devon, England

来源：

MOVEMENT DISORDERS | 2022年 / 37卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：S32 / S33

页数：2

共 50 条

[21] Ongoing clinical trials on Parkinson's disease in Europe
Eggert, K.
[J]. ACTA NEUROLOGICA SCANDINAVICA, 2008, 117 (01): : 65 - 65
[22] Issues in neuroprotection clinical trials in Parkinson's disease
Kieburtz, K
[J]. NEUROLOGY, 2006, 66 (10) : S50 - S57
[23] Minority enrollment in Parkinson's disease clinical trials
Schneider, Myra G.
Swearingen, Christopher J.
Shulman, Lisa M.
Ye, Jian
Baumgarten, Mona
Tilley, Barbara C.
[J]. PARKINSONISM & RELATED DISORDERS, 2009, 15 (04) : 258 - 262
[24] Clinical research coordinator workload in clinical trials in Parkinson's disease
Dustin, KJ
Shulman, LM
[J]. MOVEMENT DISORDERS, 2006, 21 : S121 - S121
[25] Depression in Parkinson's disease: clinical correlates and outcome
Rojo, A
Aguilar, M
Garolera, MT
Cubo, E
Navas, I
Quintana, S
[J]. PARKINSONISM & RELATED DISORDERS, 2003, 10 (01) : 23 - 28
[26] Neurologist Strategies for Optimizing the Parkinson's Disease Clinical Encounter
Schwartz, Rachel
Trivedi, Ranak
Gray, Caroline
Lorenz, Karl A.
Zulman, Donna
[J]. JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY, 2019, 32 (05) : 246 - 256
[27] An Unexpected Clinical Progression in a Parkinson's Disease Patient
Jackson, S. J.
Sheridan, R. P.
[J]. MOVEMENT DISORDERS, 2010, 25 : S649 - S649
[28] Interaction with Regulatory Agencies Worldwide to Advance the Use of Digital Health Technology in Parkinson's Disease Clinical Research: the Critical Path for Parkinson's Pre-Competitive 3DT Initiative
Mueller, M.
Cosman, J.
Adams, J. L.
Badawy, R.
Bhatnagar, R.
Bloem, B.
Carroll, C.
Cooray, N.
Dam, T.
Dexter, D. T.
Dockendorf, M.
Dorsey, E. R.
Frasier, M.
Garcia-Gancedo, L.
Hill, D.
Kostrzebski, M.
Kunka, E.
Lindemann, M.
Mammen, J.
Meinders, M.
Mirelman, A.
Roussos, G.
Sardar, S.
Simuni, T.
Speck, R.
Stebbins, G. T.
Barowicz, K. Ward
Cedarbaum, J. M.
Stephenson, D.
[J]. MOVEMENT DISORDERS, 2022, 37 : S21 - S22
[29] New Clinical Trials for Nonmotor Manifestations of Parkinson's Disease
Schrag, Anette
Sauerbier, Anna
Chaudhuri, Kallol Ray
[J]. MOVEMENT DISORDERS, 2015, 30 (11) : 1490 - 1503
[30] The impact of placebo assignment in clinical trials of Parkinson's disease
Goetz, CG
Janko, K
Blasucci, L
Jaglin, JA
[J]. ANNALS OF NEUROLOGY, 2002, 52 (03) : S34 - S34

← 1 2 3 4 5 →